Cancer Diagnostic Probe: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
== Development and application == |
== Development and application == |
||
The Cancer Diagnostic Probe was developed by a team led by Mohammad Abdolahad, a 2019 [[Mustafa Prize]] laureate and faculty member of the School of Electrical and Computer Engineering at the [[University of Tehran]], to facilitate the determination of cancerous [[resection margin|margin]]s.<ref name="Mustafa Prize" /> Abdolahad stated that the clinical trial for the device lasted 4 years and that up to 500 surgeries had been carried out using the CDP by 2020.<ref name="Mustafa Prize" /> According to Sayyed Ruhollah Miri, the head of the Cancer Institute at the Tehran University of Medical Sciences, the CDP reduces the diagnosis time to 1–2 minutes.<ref name="Iranian nanotechnology newsletter-2023">{{Cite web |last= |date=2023-01-09 |title=The visit of a delegate of Indian businessmen and doctors to the achievement of Iranian researchers in the treatment of breast cancer |url=https://news.nano.ir/100617 |access-date=2023-01-12 |website=Iranian nanotechnology newsletter |language=fa |archive-date=14 January 2023 |archive-url=https://web.archive.org/web/20230114061150/https://news.nano.ir/100617/ |url-status=live }}</ref> |
The Cancer Diagnostic Probe was developed by a team led by Mohammad Abdolahad, a 2019 [[Mustafa Prize]] laureate and faculty member of the School of Electrical and Computer Engineering at the [[University of Tehran]], to facilitate the determination of cancerous [[resection margin|margin]]s.<ref name="Mustafa Prize" /> Abdolahad stated that the clinical trial for the device lasted 4 years and that up to 500 surgeries had been carried out using the CDP by 2020.<ref name="Mustafa Prize" /> According to Sayyed Ruhollah Miri, the head of the Cancer Institute at the [[Tehran University of Medical Sciences]], the CDP reduces the diagnosis time to 1–2 minutes.<ref name="Iranian nanotechnology newsletter-2023">{{Cite web |last= |date=2023-01-09 |title=The visit of a delegate of Indian businessmen and doctors to the achievement of Iranian researchers in the treatment of breast cancer |url=https://news.nano.ir/100617 |access-date=2023-01-12 |website=Iranian nanotechnology newsletter |language=fa |archive-date=14 January 2023 |archive-url=https://web.archive.org/web/20230114061150/https://news.nano.ir/100617/ |url-status=live }}</ref> |
||
== Mechanism == |
== Mechanism == |
Latest revision as of 09:39, 9 May 2024
The Cancer Diagnostic Probe (CDP) is a medical device used in Iran during breast cancer surgery.[1][2] First developed by Nano Hesgar Sazan Salamt Arya, an Iranian company,[1] CDP has received medical approval in Iran, where it is used in surgical centers.[2]
Development and application
[edit]The Cancer Diagnostic Probe was developed by a team led by Mohammad Abdolahad, a 2019 Mustafa Prize laureate and faculty member of the School of Electrical and Computer Engineering at the University of Tehran, to facilitate the determination of cancerous margins.[2] Abdolahad stated that the clinical trial for the device lasted 4 years and that up to 500 surgeries had been carried out using the CDP by 2020.[2] According to Sayyed Ruhollah Miri, the head of the Cancer Institute at the Tehran University of Medical Sciences, the CDP reduces the diagnosis time to 1–2 minutes.[3]
Mechanism
[edit]The CDP device is composed of three main parts: "a disposable sensor; a wireless electrical head probe used by the surgeon; [and] a main control computer system which receives the signals from the head probe".[2] It electrochemically measures the hypoxia glycolysis metabolism in real-time "in pre-cancerous and cancerous lesions in cavity side margins".[1] It measures the release of H2O2 from cancer or atypical cells by the reverse Warburg effect.[1][4]
Reception
[edit]The development of CDP was supported by the Iranian Nano Technology Development Headquarters.[3] After receiving medical approval, this system has been used in breast cancer surgeries in Iran.[2] As of 2022[update], four U.S. patents have been published related to CDP.[5]
References
[edit]- ^ a b c d "Real-time Cancer Diagnostic Probe – Iran Advanced Clinical Training Center". Tehran University of Medical Sciences. Archived from the original on 14 January 2023. Retrieved 10 January 2023.
- ^ a b c d e f "Mustafa (pbuh) Prize laureate presented his Cancer Diagnostic Probe". Mustafa Prize. Archived from the original on 14 January 2023. Retrieved 10 January 2023.
- ^ Dabbagh, Najmeh; Abbasvandi, Fereshteh; Miripour, Zohreh Sadat; et al. (2022). "Accuracy of cancer diagnostic probe for intra‐surgical checking of cavity side margins in neoadjuvant breast cancer cases: A human model study". The International Journal of Medical Robotics and Computer Assisted Surgery. 18 (1): e2335. doi:10.1002/rcs.2335. ISSN 1478-5951. PMID 34571582. S2CID 238204138. Archived from the original on 14 January 2023. Retrieved 14 January 2023.
- ^ Miripour, Zohreh Sadat; Abbasvandi, Fereshteh; Aghaee, Parisa; et al. (2022). "Human study on cancer diagnostic probe (CDP) for real-time excising of breast positive cavity side margins based on tracing hypoxia glycolysis; checking diagnostic accuracy in non-neoadjuvant cases". Cancer Medicine. 11 (7): 1630–1645. doi:10.1002/cam4.4503. ISSN 2045-7634. PMC 8986141. PMID 35224879.